Continuous subcutaneous injection of octreotide for congtenital hyperinsulinism: efficacy and safety. - Subcutaneous continuous octreotide for congenital hyperinsulinism (SCORCH study)

Japan Agency for Medical Research and Development. Research group for the study on "Efficacy and safety of subcutaneous continuous octreotide infusion for congenital hyperinsulinism."0 个研究点目标入组 7 人开始时间: 2013年12月19日最近更新: 2023年10月17日

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

年龄范围: 2weeks-old 至 52weeks-old（—）
性别: All

入选标准

未提供

排除标准

•1) Hypoglycemic patients with causes other than hyperinsulinemia. 2) Patients with severe extrapancreatic comorbidities. a. intestinal dysfunction b. respiratory failure c. severe liver dysfunction with transaminases or bilirubin > 3x ULN for age. d. renal failure with urea nitrogen or creatinine > 3x ULN for age. e. patient with other comorbidities who would not be appropriate for enrollment.

研究者

发起方

Japan Agency for Medical Research and Development. Research group for the study on "Efficacy and safety of subcutaneous continuous octreotide infusion for congenital hyperinsulinism."

相似试验

进行中（未招募）

1 期

A trial comparing continuous subcutaneous hydrocortisone infusion (CSHI) therapy with conventional oral glucocorticoid therapy in patients with Congenital Andrenal Hyperplasia (CAH)Congenital Adrenal HyperplasiaMedDRA version: 14.1Level: LLTClassification code 10010323Term: Congenital adrenal hyperplasiaSystem Organ Class: 100000004850

EUCTR2011-005822-23-SEHaukeland University Hospital20

进行中（未招募）

不适用

A trial comparing continuous subcutaneous hydrocortisone therapy with conventional oral glucocorticoid therapy in congenital adrenal hyperplasiaCongenital adrenal hyperplasia (CAH)MedDRA version: 14.1Level: LLTClassification code 10010323Term: Congenital adrenal hyperplasiaSystem Organ Class: 100000004850

EUCTR2011-005822-23-NOHaukeland University Hospital

尚未招募

不适用

Octreotide therapy in eye disease caused due to thyroid disorders

CTRI/2019/11/022116Research Section AIIMS New Delhi

已完成

不适用

Subcutaneous injections of depot medroxyprogesterone acetate versus Leuprolide acetate for the reduction of pain associated with endometriosis in European and Asian women. A Phase III, randomized, parallel group, multinational, multicenter study including evaluations of bone mineral density and substudies of coagulation and lipid profiles.

PER-025-01PHARMACIA & UPJOHN INTERAMERICAN CORPORATION,

撤回

3 期

Continuous low dose subcutaneous lidocaine for treatment of pneumonia in COVID*19 patients. A randomised controlled (RCT) open*label phase III study.corona virusCOVID-1910024970

NL-OMON49706Stichting Dutch Covid19 Lidocaine ARDS100